181 related articles for article (PubMed ID: 16239395)
1. IKK{beta} as a target for treatment of inflammation induced bone loss.
Ruocco MG; Karin M
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv81-5. PubMed ID: 16239395
[TBL] [Abstract][Full Text] [Related]
2. Control of osteoclast activity and bone loss by IKK subunits: new targets for therapy.
Ruocco MG; Karin M
Adv Exp Med Biol; 2007; 602():125-34. PubMed ID: 17966397
[TBL] [Abstract][Full Text] [Related]
3. Regulation and function of IKK and IKK-related kinases.
Häcker H; Karin M
Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224
[TBL] [Abstract][Full Text] [Related]
4. Rheumatic diseases: the effects of inflammation on bone.
Walsh NC; Crotti TN; Goldring SR; Gravallese EM
Immunol Rev; 2005 Dec; 208():228-51. PubMed ID: 16313352
[TBL] [Abstract][Full Text] [Related]
5. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
Anandarajah AP; Schwarz EM
J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
[TBL] [Abstract][Full Text] [Related]
6. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
7. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
Ichikawa H; Murakami A; Aggarwal BB
Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
[TBL] [Abstract][Full Text] [Related]
8. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
9. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
10. Licochalcone A potently inhibits tumor necrosis factor alpha-induced nuclear factor-kappaB activation through the direct inhibition of IkappaB kinase complex activation.
Funakoshi-Tago M; Tanabe S; Tago K; Itoh H; Mashino T; Sonoda Y; Kasahara T
Mol Pharmacol; 2009 Oct; 76(4):745-53. PubMed ID: 19592502
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
[TBL] [Abstract][Full Text] [Related]
12. RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T; Nakashima T; Hiroshi N; Penninger JM
Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
[TBL] [Abstract][Full Text] [Related]
13. Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression.
Shishodia S; Aggarwal BB
Oncogene; 2006 Mar; 25(10):1463-73. PubMed ID: 16331273
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
Blair JM; Zhou H; Seibel MJ; Dunstan CR
Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
[TBL] [Abstract][Full Text] [Related]
15. Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption.
Cozzani M; Giovannini I; Naccari R; Penolazzi L; Lambertini E; Borgatti M; Piva R; Gambari R; Siciliani G
Prog Orthod; 2005; 6(2):238-47. PubMed ID: 16276433
[No Abstract] [Full Text] [Related]
16. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
[TBL] [Abstract][Full Text] [Related]
17. IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis.
Schopf L; Savinainen A; Anderson K; Kujawa J; DuPont M; Silva M; Siebert E; Chandra S; Morgan J; Gangurde P; Wen D; Lane J; Xu Y; Hepperle M; Harriman G; Ocain T; Jaffee B
Arthritis Rheum; 2006 Oct; 54(10):3163-73. PubMed ID: 17009244
[TBL] [Abstract][Full Text] [Related]
18. A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.
Wen D; Nong Y; Morgan JG; Gangurde P; Bielecki A; Dasilva J; Keaveney M; Cheng H; Fraser C; Schopf L; Hepperle M; Harriman G; Jaffee BD; Ocain TD; Xu Y
J Pharmacol Exp Ther; 2006 Jun; 317(3):989-1001. PubMed ID: 16525037
[TBL] [Abstract][Full Text] [Related]
19. Magnolol suppresses NF-kappaB activation and NF-kappaB regulated gene expression through inhibition of IkappaB kinase activation.
Tse AK; Wan CK; Zhu GY; Shen XL; Cheung HY; Yang M; Fong WF
Mol Immunol; 2007 Apr; 44(10):2647-58. PubMed ID: 17240450
[TBL] [Abstract][Full Text] [Related]
20. Nuclear factor-kappa B in intestinal protection and destruction.
Spehlmann ME; Eckmann L
Curr Opin Gastroenterol; 2009 Mar; 25(2):92-9. PubMed ID: 19528876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
